This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strumberg, D. Articles by Schwartz, B. Search for Related Content PubMed PubMed Citation Articles by Strumberg, D. Articles by Schwartz, B.

Clinical Pharmacology

Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

^aDepartment of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Herne, Germany; ^bMassachusetts General Hospital Cancer Center, Boston, Massachusetts, USA; ^cJules Bordet Institute, Brussels, Belgium; ^dPrincess Margaret Hospital, Toronto, Ontario, Canada; ^eJuravinski Cancer Center, Hamilton, Ontario, Canada; ^fDana-Farber Cancer Institute, Boston, Massachusetts, USA; ^gUniversity of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA; ^hBayer Pharmaceuticals Corporation, West Haven, Connecticut, USA

Key Words. Sorafenib • BAY 43-9006 • Phase I clinical trials • Review

Correspondence: Dirk Strumberg, M.D., Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Hölkeskampring 40, D-44621 Herne, Germany. Telephone: 49-2323-499-5252; Fax: 49-2323-499-1578; e-mail: dirk.strumberg{at}marienhospital-herne.de

Sorafenib is an oral multikinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases involved in tumor growth and angiogenesis. It has demonstrated preclinical and clinical activity in several tumor types. Sorafenib 400 mg twice daily (bid) has been approved in several countries worldwide for the treatment of renal cell carcinoma. This review summarizes key safety, pharmacokinetic, and efficacy data from four phase I, single-agent, dose-escalation studies with sorafenib in patients with advanced refractory solid tumors (n = 173). These trials followed different treatment regimens (7 days on/7 days off, n = 19; 21 days on/7 days off, n = 44; 28 days on/7 days off, n = 41; or continuous dosing, n = 69) to establish the optimum dosing schedule. Sorafenib was generally well tolerated; most adverse events were mild to moderate in severity up to the defined maximum-tolerated dose of 400 mg twice daily (bid). The most frequently reported drug-related adverse events at any grade included fatigue (40%), anorexia (35%), diarrhea (34%), rash/desquamation (27%), and hand–foot skin reaction (25%). Sorafenib demonstrated preliminary antitumor activity, particularly among patients with renal cell carcinoma or hepatocellular carcinoma: overall, two of 137 evaluable patients achieved partial responses and 38 (28%) had stable disease. Although there was high interpatient variability in plasma pharmacokinetics across these studies, this was not associated with an increased incidence or severity of toxicity. Preliminary studies suggest that phosphorylated extracellular signal–related kinase in tumor cells or peripheral blood lymphocytes may be a useful biomarker for measuring and, ultimately, predicting the effects of sorafenib. Based on these findings, continuous daily 400 mg bid sorafenib was chosen as the optimal regimen for phase II/III studies. Trials are ongoing in renal cell carcinoma, hepatocellular carcinoma, melanoma, and non-small cell lung cancer.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				N. P. Shah, D.-W. Kim, H. Kantarjian, P. Rousselot, P. E. D. Llacer, A. Enrico, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, M. C. Muller, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib Haematologica, February 1, 2010; 95(2): 232 - 240. [Abstract] [Full Text] [PDF]

				M. Guillet, T. Walter, J.-Y. Scoazec, T. Vial, C. Lombard-Bohas, and J. Dumortier Sorafenib-Induced Bilateral Osteonecrosis of Femoral Heads J. Clin. Oncol., January 10, 2010; 28(2): e14 - e14. [Full Text] [PDF]

				K. Takezawa, I. Okamoto, K. Yonesaka, E. Hatashita, Y. Yamada, M. Fukuoka, and K. Nakagawa Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells Cancer Res., August 15, 2009; 69(16): 6515 - 6521. [Abstract] [Full Text] [PDF]

				J.-Y. Liu, S.-H. Park, C. Morisseau, S. H. Hwang, B. D. Hammock, and R. H. Weiss Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo Mol. Cancer Ther., August 1, 2009; 8(8): 2193 - 2203. [Abstract] [Full Text] [PDF]

				A. Kim, F. M. Balis, and B. C. Widemann Sorafenib and Sunitinib Oncologist, August 1, 2009; 14(8): 800 - 805. [Full Text] [PDF]

				S. I. Sherman Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1493 - 1499. [Abstract] [Full Text] [PDF]

				B. Escudier, C. Szczylik, T. E. Hutson, T. Demkow, M. Staehler, F. Rolland, S. Negrier, N. Laferriere, U. J. Scheuring, D. Cella, et al. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., March 10, 2009; 27(8): 1280 - 1289. [Abstract] [Full Text] [PDF]

				N. S. Azad, J. B. Aragon-Ching, W. L. Dahut, M. Gutierrez, W. D. Figg, L. Jain, S. M. Steinberg, M. L. Turner, E. C. Kohn, and H. H. Kong Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy Clin. Cancer Res., February 15, 2009; 15(4): 1411 - 1416. [Abstract] [Full Text] [PDF]

				L. Jilaveanu, C. Zito, S. J. Lee, K. L. Nathanson, R. L. Camp, D. L. Rimm, K. T. Flaherty, and H. M. Kluger Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib Clin. Cancer Res., February 1, 2009; 15(3): 1076 - 1085. [Abstract] [Full Text] [PDF]

				R. Houben, H. Voigt, C. Noelke, V. Hofmeister, J. C. Becker, and D. Schrama MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib Mol. Cancer Ther., February 1, 2009; 8(2): 433 - 440. [Abstract] [Full Text] [PDF]

				Y. Will, J. A. Dykens, S. Nadanaciva, B. Hirakawa, J. Jamieson, L. D. Marroquin, J. Hynes, S. Patyna, and B. A. Jessen Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells Toxicol. Sci., November 1, 2008; 106(1): 153 - 161. [Abstract] [Full Text] [PDF]

				F. Yang, T. E. Van Meter, R. Buettner, M. Hedvat, W. Liang, C. M. Kowolik, N. Mepani, J. Mirosevich, S. Nam, M. Y. Chen, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas Mol. Cancer Ther., November 1, 2008; 7(11): 3519 - 3526. [Abstract] [Full Text] [PDF]

				B. Dewaele, B. Wasag, J. Cools, R. Sciot, H. Prenen, P. Vandenberghe, A. Wozniak, P. Schoffski, P. Marynen, and M. Debiec-Rychter Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation Clin. Cancer Res., September 15, 2008; 14(18): 5749 - 5758. [Abstract] [Full Text] [PDF]

				L. Dal Lago, V. D'Hondt, and A. Awada Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors Oncologist, August 1, 2008; 13(8): 845 - 858. [Abstract] [Full Text] [PDF]

				N. P. Shah, H. M. Kantarjian, D.-W. Kim, D. Rea, P. E. Dorlhiac-Llacer, J. H. Milone, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, A. Charbonnier, et al. Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia J. Clin. Oncol., July 1, 2008; 26(19): 3204 - 3212. [Abstract] [Full Text] [PDF]

				C. Montagut, S. V. Sharma, T. Shioda, U. McDermott, M. Ulman, L. E. Ulkus, D. Dias-Santagata, H. Stubbs, D. Y. Lee, A. Singh, et al. Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma Cancer Res., June 15, 2008; 68(12): 4853 - 4861. [Abstract] [Full Text] [PDF]

				S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia Mol. Cancer Ther., May 1, 2008; 7(5): 1110 - 1120. [Abstract] [Full Text] [PDF]

				L. Moreno-Vinasco, M. Gomberg-Maitland, M. L. Maitland, A. A. Desai, P. A. Singleton, S. Sammani, L. Sam, Y. Liu, A. N. Husain, R. M. Lang, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension Physiol Genomics, April 1, 2008; 33(2): 278 - 291. [Abstract] [Full Text] [PDF]

				T. Diago, J. S. Pulido, J. R. Molina, L. C. Collet, T. P. Link, and E. H. Ryan Jr Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration Mayo Clin. Proc., February 1, 2008; 83(2): 231 - 234. [Abstract] [Full Text] [PDF]

				L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]